https://rijournals.com/scientific-and-experimental-sciences/

RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):85-85, 2025

©RIJSES Publications

ONLINE ISSN: 1115-618X

PRINT ISSN: 1597-2917

https://doi.org/10.59298/RIJSES/2025/528085

The Role of Alkaloids in Regulating Glucose Homeostasis and Adiposity: Implications for Obesity and Diabetes Therapy

Kamanzi Ntakirutimana G.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Obesity and type 2 diabetes (T2D) are globally prevalent metabolic disorders with multifactorial etiologies, including insulin resistance, impaired glucose homeostasis, and dysregulated lipid metabolism. In recent years, plant-derived alkaloids have emerged as promising bioactive compounds capable of modulating metabolic pathways, offering potential therapeutic benefits for managing obesity and diabetes. Alkaloids, known for their diverse biological activities, have demonstrated antidiabetic and anti-obesity effects through various mechanisms, such as enhancing insulin signaling, reducing adiposity, and improving lipid metabolism. This review comprehensively examines the role of alkaloids in regulating glucose homeostasis and adiposity, exploring their impact on insulin resistance, adipogenesis, and lipid metabolic pathways. Specific alkaloids, such as berberine, metformin, and capsaicin, have shown remarkable promise in preclinical and clinical studies. The underlying molecular mechanisms include modulation of key signaling pathways such as AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptors (PPARs), and the insulin receptor. We also discuss the potential advantages and challenges of alkaloid-based therapies and highlight their implications for the treatment of obesity and diabetes. The review concludes with an exploration of future directions for the development of alkaloid-based drugs in the management of metabolic disorders.

Keywords: Alkaloids, Glucose Homeostasis, Adiposity, Obesity, Diabetes, Insulin Signaling, Lipid Metabolism, Insulin Resistance, Plant-based Therapy

INTRODUCTION

The growing global burden of obesity and type 2 diabetes (T2D) has become a significant public health challenge, with the increasing prevalence of these conditions across various populations[1–4]. Obesity, often driven by unhealthy lifestyles and poor dietary habits, is characterized by an excessive accumulation of body fat, which leads to insulin resistance. Insulin resistance impairs the ability of cells to effectively respond to insulin, a hormone crucial for regulating blood sugar levels[3]. Over time, this disruption in insulin signaling contributes to the development of T2D, a metabolic disorder marked by chronic hyperglycemia[5, 6]. T2D is primarily caused by defects in insulin secretion and glucose metabolism, which are exacerbated by obesity. As both conditions share common pathophysiological mechanisms, addressing one often involves managing the other. Given the increasing rates of obesity and T2D worldwide, the search for novel therapeutic strategies has become a priority[7].

In recent years, plant-derived compounds have gained significant attention for their potential to regulate glucose homeostasis and reduce adiposity, providing an alternative or complementary approach to conventional drug therapies[7]. Alkaloids, a diverse group of nitrogen-containing secondary metabolites found in various plant species, have emerged as promising candidates in the management of metabolic disorders[8]. These compounds, known for their wide range of biological activities, have been shown to exhibit antidiabetic and anti-obesity effects through several mechanisms. One of the key actions of alkaloids is their ability to modulate insulin signaling pathways, which plays a crucial role in improving insulin sensitivity and glucose uptake in target tissues[9]. Additionally, alkaloids can influence glucose metabolism by promoting increased glucose utilization and inhibiting hepatic glucose production, both of which are vital for maintaining normal blood sugar levels.

These effects suggest that alkaloids may offer a natural alternative to synthetic drugs for managing hyperglycemia in individuals with T2D.
Alkaloids also demonstrate potential benefits in addressing obesity, another critical factor in the development and progression of T2D[10, 11]. These compounds have been found to modulate lipid metabolism and adipocyte function, reducing excessive fat accumulation. Some alkaloids act by enhancing thermogenesis, the process by which the body generates heat by burning fat. This mechanism not only helps to reduce adiposity but also improves overall energy balance.[12] Furthermore, alkaloids may exert anti-inflammatory effects, which are beneficial in mitigating the chronic low-grade inflammation commonly seen in obesity and T2D. The ability of alkaloids to target multiple aspects of metabolic dysfunction, including insulin resistance, glucose metabolism, and lipid homeostasis, makes them attractive candidates for the development of therapeutic agents aimed at treating both obesity and T2D[13]. As research continues to explore the full range of alkaloid-derived compounds, there is growing potential for their incorporation into integrated strategies for the management of these pervasive metabolic disorders.

Alkaloids and Their Mechanisms of Action

Insulin Signaling Pathway: Alkaloids exert significant biological effects on glucose metabolism, particularly through the enhancement of insulin signaling. For instance, berberine, a well-known alkaloid, has been shown to increase insulin receptor activity, which results in improved insulin sensitivity and glucose uptake in peripheral tissues[14]. These effects are primarily mediated by the activation of intracellular signaling molecules such as AMP-activated protein kinase (AMPK). AMPK plays a crucial role in maintaining energy balance by regulating both glucose and lipid metabolism. In this way, alkaloids improve glucose homeostasis by enhancing insulin action and facilitating glucose transport into cells, especially in muscle and adipose tissue[14]. By improving insulin sensitivity, alkaloids like berberine can help regulate blood sugar levels and prevent insulin resistance, a key factor in the development of type 2 diabetes. These effects highlight the therapeutic potential of alkaloids as natural agents for managing metabolic disorders related to glucose imbalance.
AMPK Activation: AMP-activated protein kinase (AMPK) serves as a master regulator of energy homeostasis and is central to both glucose and lipid metabolism. Alkaloids, including berberine and capsaicin, activate AMPK, leading to several beneficial metabolic outcomes. AMPK activation promotes glucose uptake in cells by increasing the translocation of glucose transporters to the plasma membrane, enhancing cellular glucose utilization[15]. Additionally, AMPK stimulates fat oxidation while inhibiting lipid synthesis, contributing to reduced lipid accumulation in adipocytes. These actions help improve metabolic efficiency and prevent obesity-related complications. By regulating both glucose and lipid metabolism, alkaloids that activate AMPK can enhance energy expenditure and combat insulin resistance, making them potential therapeutic agents for conditions such as obesity and type 2 diabetes[16]. The ability of alkaloids to regulate AMPK underscores their promising role in metabolic health, offering a natural means of improving energy balance and preventing metabolic diseases.
PPAR Modulation: Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptors that play a pivotal role in the regulation of fatty acid metabolism, adipogenesis, and overall lipid homeostasis. Alkaloids, such as berberine and capsaicin, have been found to modulate the activity of PPARs, leading to improved lipid metabolism[17]. Activation of PPARα, for instance, enhances the oxidation of fatty acids, while activation of PPARγ inhibits adipogenesis, the process by which pre-adipocytes differentiate into fat cells. Through these mechanisms, alkaloids can promote the breakdown of fatty acids for energy and prevent excessive fat accumulation in adipose tissue, thereby mitigating the risk of obesity. These effects also extend to the modulation of other metabolic pathways, including the regulation of cholesterol and triglyceride levels.[17] By targeting PPARs, alkaloids provide a potential avenue for managing obesity and metabolic disorders. The ability of alkaloids to modulate PPAR activity highlights their role as natural agents in the treatment of metabolic diseases, improving fat metabolism and reducing adiposity.

Alkaloids in Obesity Therapy

Alkaloids have demonstrated significant anti-obesity effects through their ability to regulate appetite, inhibit adipogenesis, and promote fat oxidation[18].
Adipogenesis Inhibition: Alkaloids such as capsaicin and berberine have been shown to inhibit adipogenesis, the process through which preadipocytes differentiate into mature adipocytes[19]. This reduction in adipocyte formation can help decrease adipose tissue accumulation, particularly in visceral fat, which is linked to various metabolic disorders. Capsaicin, found in chili peppers, has been found to influence several molecular pathways involved in adipocyte differentiation, including the inhibition of key transcription factors such as PPARγ, which plays a central role in adipogenesis. Similarly, berberine, an alkaloid derived from plants like Goldenseal, has been reported to decrease fat accumulation by suppressing the expression of adipogenesis-related genes[19]. Both of these alkaloids also exhibit anti-inflammatory properties, which further support the reduction of fat tissue accumulation. The inhibition of adipogenesis can be a valuable therapeutic strategy in managing obesity and its associated conditions, including diabetes and cardiovascular diseases. These alkaloids hold potential as

natural compounds in weight management by limiting the expansion of fat stores and promoting metabolic health.

Fat Oxidation Enhancement: Several alkaloids have been identified as potent enhancers of fat oxidation, which is critical for the breakdown of stored fats and the conversion of fatty acids into energy[20]. One of the most well-studied alkaloids in this regard is capsaicin. Capsaicin activates AMP-activated protein kinase (AMPK), a cellular energy sensor that plays a crucial role in regulating metabolic processes. AMPK activation enhances mitochondrial biogenesis and promotes lipid catabolism, thereby increasing fat oxidation[21]. This process not only accelerates the breakdown of fatty acids but also improves the efficiency of energy production within cells. Similarly, berberine has been shown to stimulate fat oxidation by activating AMPK, leading to increased mitochondrial activity and a shift toward energy expenditure rather than fat storage. These alkaloids have been explored as potential therapeutic agents for managing obesity and improving metabolic health by enhancing fat metabolism[22]. By increasing fat oxidation, they contribute to greater fat loss, reduce fat accumulation, and support overall weight management. Furthermore, their effects on mitochondrial function suggest additional benefits for metabolic conditions like type 2 diabetes and cardiovascular diseases.

Appetite Suppression: Certain alkaloids, including capsaicin, have been demonstrated to suppress appetite, contributing to weight loss and improved metabolic outcomes[23]. Capsaicin, the active compound in chili peppers, has been shown to modulate appetite-regulating hormones such as ghrelin and leptin. Ghrelin, often referred to as the "hunger hormone," stimulates appetite, while leptin, known as the "satiety hormone," helps reduce food intake[23]. Capsaicin reduces ghrelin levels, which in turn leads to decreased hunger, and it enhances leptin sensitivity, promoting satiety. This dual action results in reduced food consumption and overall calorie intake. Additionally, capsaicin's thermogenic effects increase energy expenditure, further supporting weight management. Other alkaloids, like berberine, may also contribute to appetite suppression through similar mechanisms[24]. Berberine has been shown to influence the gut microbiota and improve insulin sensitivity, which could indirectly affect appetite control. By targeting the hormonal regulation of appetite and enhancing energy expenditure, these alkaloids provide a promising natural approach for obesity management and appetite control, offering potential benefits for individuals struggling with overeating and weight gain.

Alkaloids in Diabetes Therapy

The management of type 2 diabetes (T2D) requires improving insulin sensitivity, regulating blood glucose levels, and preventing complications associated with chronic hyperglycemia [25]. Alkaloids, a diverse group of naturally occurring compounds, have been shown to exert potent antidiabetic effects through several mechanisms, making them promising candidates in managing T2D. These compounds can help regulate glucose metabolism and offer therapeutic benefits for patients with T2D. Alkaloids, like berberine, have been extensively studied for their insulin-sensitizing properties, and their ability to modulate signaling pathways crucial for glucose homeostasis is one of the reasons they are considered effective in managing T2D[26].

Insulin Sensitization: Alkaloids, particularly berberine, play a crucial role in improving insulin sensitivity, which is often impaired in individuals with T2D[27]. Berberine achieves this by activating AMP-activated protein kinase (AMPK), a key regulator of cellular energy balance. AMPK activation helps enhance insulin sensitivity by modulating the activity of insulin receptor substrates, thus promoting more efficient glucose uptake by peripheral tissues, such as skeletal muscle and adipose tissue[27]. Furthermore, AMPK activation helps regulate lipid and glucose metabolism, improving overall metabolic function in patients with T2D. This action contributes to reducing insulin resistance, which is a hallmark of T2D.

Glucose Uptake Enhancement: Alkaloids have also been found to enhance glucose uptake in peripheral tissues, such as skeletal muscle and adipose tissue[28]. This occurs through insulin-independent mechanisms, which are especially beneficial for individuals with T2D who often exhibit impaired insulin response. By promoting glucose uptake through mechanisms independent of insulin, alkaloids help to lower blood glucose levels without depending on insulin secretion[28]. This insulin-independent action can be particularly beneficial for patients with advanced stages of T2D, where insulin production may be compromised. The ability of alkaloids to stimulate glucose uptake in tissues allows for more efficient utilization of glucose, helping to maintain blood glucose homeostasis[29].

Reduction of Hepatic Glucose Production: Berberine and other alkaloids have been shown to reduce hepatic glucose production, a major contributor to elevated blood glucose levels in T2D. Alkaloids inhibit the expression of genes involved in gluconeogenesis, the process by which the liver produces glucose from non-carbohydrate precursors[30]. By downregulating key enzymes involved in gluconeogenesis, such as glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, alkaloids help to reduce excessive glucose production by the liver[30,31,32,33,34,35]. This action helps control blood glucose levels and is beneficial for patients with T2D, where hepatic glucose production is often dysregulated. By modulating hepatic glucose production, alkaloids contribute to overall glycemic control and help prevent the complications associated with chronic hyperglycemia.

Clinical Evidence and Therapeutic Implications

Several alkaloids, especially berberine, have demonstrated promising effects in managing obesity and type 2 diabetes (T2D) in clinical trials. Berberine, a plant-derived alkaloid, has been found to significantly reduce fasting blood glucose levels, enhance insulin sensitivity, and promote weight loss in individuals with T2D [36,37,38,39,40]. These beneficial effects are attributed to its ability to activate AMP-activated protein kinase (AMPK), a key regulator of energy metabolism. Other alkaloids, such as capsaicin, the active component in chili peppers, have also shown potential in clinical studies. Capsaicin has been reported to reduce adiposity, improve glucose tolerance, and modulate lipid metabolism, making it an attractive candidate for T2D management [32,41]. Despite the promising results, there are challenges that need to be overcome for the widespread clinical use of these alkaloids. One major obstacle is their low bioavailability, which limits their therapeutic potential. The poor absorption and rapid metabolism of alkaloids in the body hinder their effectiveness, requiring higher doses to achieve desired effects, which may increase the risk of side effects. Furthermore, potential adverse effects such as gastrointestinal discomfort or drug interactions must be carefully monitored. Therefore, improving the formulation and delivery methods of alkaloids is essential for their broader application in treating obesity and T2D[32].

Challenges and Future Directions

While alkaloids present a promising therapeutic avenue for managing obesity and diabetes, several challenges remain. Low bioavailability, rapid metabolism, and limited absorption are common issues associated with alkaloid-based therapies. Future research should focus on optimizing the pharmacokinetics of alkaloids through the development of novel delivery systems, such as nanoparticles or liposomal formulations. Additionally, clinical trials with larger sample sizes and longer durations are needed to fully assess the efficacy and safety of alkaloids in the management of metabolic disorders.

CONCLUSION

Alkaloids, derived from plants, hold significant promise in the regulation of glucose homeostasis and adiposity, offering potential therapeutic benefits for the treatment of obesity and T2D. Through their effects on insulin signaling, lipid metabolism, and adipogenesis, alkaloids represent a novel approach to managing these prevalent metabolic disorders. However, further research is needed to overcome challenges related to their bioavailability and to establish their clinical efficacy.

REFERENCES

1. Solverson, P.: Anthocyanin Bioactivity in Obesity and Diabetes: The Essential Role of Glucose Transporters in the Gut and Periphery. Cells. 9, 2515 (2020). https://doi.org/10.3390/cells9112515
2. Amor, A.J., Gómez-Guerrero, C., Ortega, E., Sala-Vila, A., Lázaro, I.: Ellagic Acid as a Tool to Limit the Diabetes Burden: Updated Evidence. Antioxidants. 9, 1226 (2020). https://doi.org/10.3390/antiox9121226
3. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
4. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
5. Altamura, S., Müdder, K., Schlotterer, A., Fleming, T., Heidenreich, E., Qiu, R., Hammes, H.-P., Nawroth, P., Muckenthaler, M.U.: Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload. Mol. Metab. 51, 101235 (2021). https://doi.org/10.1016/j.molmet.2021.101235
6. Alum, E.U., Krishnamoorthy, R., Gatasheh, M.K., Subbarayan, S., Vijayalakshmi, P., Uti, D.E.: Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: In Vivo and in Silico Evidence. Nat. Prod. Commun. 19, 1934578X241299279 (2024). https://doi.org/10.1177/1934578X241299279
7. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
8. Mohammed, N.J., Al-Behadili, W.A.A.: The Chemical Structure, Classification and Clinical Significance of Alkaloids. Int. J. Health Med. Res. 03, (2024). https://doi.org/10.58806/ijhmr.2024.v3i10n10
9. Dhalsamant, K., Singh, C.B., Lankapalli, R.: A Review on Greening and Glycoalkaloids in Potato Tubers: Potential Solutions. J. Agric. Food Chem. 70, 13819−13831 (2022). https://doi.org/10.1021/acs.jafc.2c01169
10. Nepal, B., J. Stine, K.: Glycoalkaloids: Structure, Properties, and Interactions with Model Membrane Systems. Processes. 7, 513 (2019). https://doi.org/10.3390/pr7080513
11. Chandrasekaran, P., Weiskirchen, R.: The Role of Obesity in Type 2 Diabetes Mellitus—An Overview. Int. J. Mol. Sci. 25, 1882 (2024). https://doi.org/10.3390/ijms25031882

12. Hu, W., Yan, G., Ding, Q., Cai, J., Zhang, Z., Zhao, Z., Lei, H., Zhu, Y.Z.: Update of Indoles: Promising molecules for ameliorating metabolic diseases. Biomed. Pharmacother. 150, 112957 (2022). https://doi.org/10.1016/j.biopha.2022.112957
13. Behl, T., Gupta, A., Albratty, M., Najmi, A., Meraya, A.M., Alhazmi, H.A., Anwer, Md.K., Bhatia, S., Bungau, S.G.: Alkaloidal Phytoconstituents for Diabetes Management: Exploring the Unrevealed Potential. Molecules. 27, 5851 (2022). https://doi.org/10.3390/molecules27185851
14. Xu, X., Yi, H., Wu, J., Kuang, T., Zhang, J., Li, Q., Du, H., Xu, T., Jiang, G., Fan, G.: Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed. Pharmacother. 133, 110984 (2021). https://doi.org/10.1016/j.biopha.2020.110984
15. Srivastava, R.A.K., Pinkosky, S.L., Filippov, S., Hanselman, J.C., Cramer, C.T., Newton, R.S.: AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J. Lipid Res. 53, 2490–2514 (2012). https://doi.org/10.1194/jlr.R025882
16. Balasubramani, S.P., Armstead, S.A., Buggs, A.T., Bell, M.S.: Mito-Nutraceutical Potential of Plant Secondary Metabolites. Fortune J. Health Sci. 8, 217–244 (2025)
17. Christofides, A., Konstantinidou, E., Jani, C., Boussiotis, V.A.: The role of Peroxisome Proliferator-Activated Receptors (PPAR) in immune responses. Metabolism. 114, 154338 (2021). https://doi.org/10.1016/j.metabol.2020.154338
18. Ezichi Favour, O., Chinwendu Angela, O., Tiffany Ezinne, G., Chioma Juliet, A., Sandra C, O., Simeon, B., Chidera Godson, C., Uzochukwu Eric, O., Chibuzo Collette, A., Justina Onyinyechi, O., Henry Nnaemeka, O.: Current Insights on the Effects of Medicinal Plants in the Management of Obesity and Infectious Diseases: An Update from 2020. Asp. Mol. Med. 100075 (2025). https://doi.org/10.1016/j.amolm.2025.100075
19. Ariyanto, E.F., Wirajati, F., Rahman, P.H., Berbudi, A., Rohmawaty, E.: Mechanism of action of Indonesian medicinal plants in inhibiting 3T3-L1 adipocyte differentiation: A review. J. Appl. Pharm. Sci. 13, 050–057 (2023). https://doi.org/10.7324/JAPS.2023.6711
20. Edwards, M., Mohiuddin, S.S.: Biochemistry, Lipolysis. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
21. Vockley, J.: Long-Chain Fatty Acid Oxidation Disorders and Current Management Strategies. Am. J. Manag. Care. 26, S147–S154 (2020). https://doi.org/10.37765/ajmc.2020.88480
22. Ma, Z., Wang, S., Miao, W., Zhang, Z., Yu, L., Liu, S., Luo, Z., Liang, H., Yu, J., Huang, T., Li, M., Gao, J., Su, S., Li, Y., Zhou, L.: The Roles of Natural Alkaloids and Polyphenols in Lipid Metabolism: Therapeutic Implications and Potential Targets in Metabolic Diseases. Curr. Med. Chem. 30, 3649–3667 (2023). https://doi.org/10.2174/0929867330666221107095646
23. Szallasi, A.: Capsaicin for Weight Control: "Exercise in a Pill" (or Just Another Fad)? Pharmaceuticals. 15, 851 (2022). https://doi.org/10.3390/ph15070851
24. Wang, Y., Zhou, Y., Fu, J.: Advances in antiobesity mechanisms of capsaicin. Curr. Opin. Pharmacol. 61, 1–5 (2021). https://doi.org/10.1016/j.coph.2021.08.012
25. Alum, E., P.C., U., Obeagu, E., Aja, P., Ugwu, C., Okon, M.: NUTRITIONAL CARE IN DIABETES MELLITUS: A COMPREHENSIVE GUIDE. 11, 16–15 (2023). https://doi.org/10.58538/IJIAR/2057
26. Utami, A.R., Maksum, I.P., Deawati, Y.: Berberine and Its Study as an Antidiabetic Compound. Biology. 12, 973 (2023). https://doi.org/10.3390/biology12070973
27. Yin, J., Ye, J., Jia, W.: Effects and mechanisms of berberine in diabetes treatment. Acta Pharm. Sin. B. 2, 327–334 (2012). https://doi.org/10.1016/j.apsb.2012.06.003
28. Alam, S., Sarker, Md.M.R., Sultana, T.N., Chowdhury, Md.N.R., Rashid, M.A., Chaity, N.I., Zhao, C., Xiao, J., Hafez, E.E., Khan, S.A., Mohamed, I.N.: Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development. Front. Endocrinol. 13, 800714 (2022). https://doi.org/10.3389/fendo.2022.800714
29. Adhikari, B.: Roles of Alkaloids from Medicinal Plants in the Management of Diabetes Mellitus. J. Chem. 2021, 2691525 (2021). https://doi.org/10.1155/2021/2691525
30. Li, A., Liu, Q., Li, Q., Liu, B., Yang, Y., Zhang, N.: Berberine Reduces Pyruvate-driven Hepatic Glucose Production by Limiting Mitochondrial Import of Pyruvate through Mitochondrial Pyruvate Carrier 1. EBioMedicine. 34, 243–255 (2018). https://doi.org/10.1016/j.ebiom.2018.07.039
31. Yin, J., Xing, H., Ye, J.: Efficacy of Berberine in Patients with Type 2 Diabetes. Metabolism. 57, 712–717 (2008). https://doi.org/10.1016/j.metabol.2008.01.013
32. Bort, A., Sánchez, B.G., Spínola, E., Mateos-Gómez, P.A., Rodríguez-Henche, N., Díaz-Laviada, I.: The red pepper's spicy ingredient capsaicin activates AMPK in HepG2 cells through CaMKKβ. PloS One. 14, e0211420 (2019). https://doi.org/10.1371/journal.pone.0211420

33. Aja PM, IO Igwenyi, PU Okechukwu, OU Orji, EU Alum. Evaluation of anti-diabetic effect and liver function indices of ethanol extracts of Moringa oleifera and Cajanus cajan leaves in alloxan induced diabetic albino rats Global Veterinaria 14(3) 439-447 (2015).
34. Offor CE, OPC Ugwu, EU Alum. The anti-diabetic effect of ethanol leaf-extract of Allium sativum on Albino rats. International Journal of Pharmacy and Medical Sciences, 4, (1), 01-03 (2014).
35. Enechi OC, H Ikenna Oluka, PC Okechukwu Ugwu. Acute toxicity, lipid peroxidation and ameliorative properties of Alstonia boonei ethanol leaf extract on the kidney markers of alloxan induced diabetic rats. African journal of biotechnology, 13, 5 (2014).
36. Adonu CC, OP Ugwu, A Bawa, EC Ossai, AC Nwaka. Intrinsic blood coagulation studies in patients suffering from both diabetes and hypertension. Int Journal of Pharmaceutical Medicine and Bio Science, 2 (2), 36-45 (2013).
37. Okechukwu Paul-Chima Ugwu, Esther Ugo Alum, Michael Ben Okon, Patrick M Aja, Emmanuel Ifeanyi Obeagu, EC Onyeneke Ethanol root extract and fractions of Sphenocentrum jollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats Oxford University Press 2(2) 10 (2023).
38. Mariam Oyedeji Amusa and Adeyinka Olufemi Adepoju Okechukwu P. C. Ugwu, Esther Ugo Alum, Emmanuel I. Obeagu, Michael Ben Okon, Patrick M. Aja , Awotunde Oluwasegun Samson Effect of Ethanol leaf extract of Chromolaena odorata on lipid profile of streptozotocin induced diabetic wistar albino rats. IAA Journal of Biological Sciences, 10, (1), 109-117 (2023).
39. Alum EU, GU Umoru, DE Uti, PM Aja, OP Ugwu, OU Orji, BU Nwali, NN Ezeani, N Edwin, FO Orinya HEPATO-PROTECTIVE EFFECT OF ETHANOL LEAF EXTRACT OF Datura stramonium in ALLOXAN-INDUCED DIABETIC ALBINO RATS. Journal of Chemical Society of Nigeria, 47, 5 (2022).
40. Ugwu Okechukwu P.C. and Amasiorah V.I. The effects of the crude ethanol root extract and fractions of Sphenocentrum jollyanum on hematological indices and glycosylated haemoglobin of streptozotocin-induced diabetic. INOSR Scientific Research, 6, (1), 61-74 (2020).
41. Enechi OC, IH Oluka, OPC Ugwu, YS Omeh Effect of ethanol leaf extract of Alstonia boonei on the lipid profile of alloxan induced diabetic rats. World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS), 2013, Vol. 2, No. 3, 782-795(2012).

CITE AS: Kamanzi Ntakirutimana G. (2025). The Role of Alkaloids in Regulating Glucose Homeostasis and Adiposity: Implications for Obesity and Diabetes Therapy. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):80-85. https://doi.org/10.59298/RIJSES/2025/528085